- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04010799
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
A Phase Ib, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6333 After Single and Repeated Ascending Doses in Patients Affected by Cystic Fibrosis and Non Cystic Fibrosis Bronchiectasis
CHF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases.
CHF6333 is an inhaled anti-inflammatory which mechanism of action is based on the inhibition of Human Neutrofil Elastase.
The safety and tolerability of single and repeated ascending doses of inhaled CHF 6333 was previously investigated in healthy subjects: information was gathered on the uptake, distribution and excretion of the medicinal product being tested (pharmacokinetics). In this current clinical trial CHF 6333 will be tested in patients(CF and NCFB) for the first time.
Three dose level will be tested during the first part of the study, as single administration. One repeated dose will be administered in the second part of the study.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Frankfurt/Main, Germany
- IKF Institut für klinische Forschung Pneumologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
CF patients:
- Patient's written informed consent obtained prior to any study-related procedure;
- Male or female patient ≥ 18 years old with a confirmed historical diagnosis of cystic fibrosis;
- Ability to provide a spontaneous sputum sample at screening;
- Non- or ex-smokers who smoked < 10 pack years and stopped smoking > 1 year before screening visit;
- Patient in stable clinical condition and free from exacerbation for at least 4 weeks prior to screening and/or prior to randomisation;
- Patient on stable concomitant treatment regimen within 4 weeks prior to screening and/or prior to randomisation;
- Patient with pre-bronchodilator FEV1 ≥ 50% of predicted normal at screening and/or prior to randomisation;
- Vital signs within normal limits at screening and prior to randomisation;
NCFB patients:
- Patient's written informed consent obtained prior to any study-related procedure;
- Male or female patient ≥ 18 years old with a diagnosis of Bronchiectasis confirmed by a historical Chest CT;
- Presence of clinically significant symptoms related to Bronchiectasis, such as daily cough that occurs over months or years, daily production of large amount of sputum, shortness of breath, wheezing chest pain;
- Ability to provide a spontaneous sputum sample at screening;
- Non- or ex-smokers who smoked < 10 pack years and stopped smoking > 1 year before screening visit;
- Patients in stable clinical condition and free from exacerbation since at least 4 weeks before screening and/or prior to randomisation;
- Patients on stable concomitant treatment regimen within 4 weeks prior to screening and/or prior to randomisation
- Patient with pre- bronchodilator FEV1 ≥ 50% of predicted normal at screening and/or prior randomization visit;
- Vital signs within normal limits at screening and prior to randomisation
EXCLUSION CRITERIA CF Patients
- Patient with BMI ≤ 17
- History of a clinically meaningful unstable or uncontrolled chronic comorbidity in the opinion of the Investigator;
- Unstable pulmonary status or symptomatic respiratory tract infection and related changes in therapy for pulmonary disease as per Investigator's judgment within 4 weeks before screening or prior to randomisation;
- Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation;
- History of asthma based on objective evidence;
- History of malignancy, solid organ/haematological transplantation;
- Patient with evidence of active Nontuberculous Mycobacteria (NTM) and Tuberculous Mycobacteria (TM) infection or related bronchiectasis in the past 12 months;
- Patient with a positive test for active Allergic Bronchopulmonary Aspergillosis (ABPA) infection confirmed at screening or patient withABPA related bronchiectasis.
- Pregnant or lactating women.
- Patient on non-steroidal anti-inflammatory drugs (NSAIDs) within 4 weeks prior to screening or prior to randomization visit.
- Patient on cystic fibrosis transmembrane conductance regulator (CFTR) modulators and correctors if not on stable treatment regimen for at least 3 months prior to screening or prior to randomization.
- Positive HIV1 or HIV2 serology at screening; Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening (i.e. positive HB surface antigen (HBsAg), HB core antibody (anti-HBc), HC antibody);
NCFB Patients
- Patient with BMI ≤ 17
- History of a clinically meaningful unstable or uncontrolled chronic comorbidity in the opinion of the Investigator;
- Unstable pulmonary status or symptomatic respiratory tract infection and related changes in therapy for pulmonary disease as per Investigator's judgment within 4 weeks before screening or prior to randomisation.
- Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation that results in active medical problem which may impact the safety of the patients as per Investigator's judgment.
- History of malignancy, solid organ/haematological transplantation;
- Known diagnosis of cystic fibrosis. A negative sweat test is required at screening (sweat chloride should be < 40 mmol/L);
- History of asthma based on objective evidence of the condition;
- Patient with primary diagnosis of COPD in the opinion of theInvestigator;
- Patient with rheumatoid factor positivity;
- Patient with evidence of active Nontuberculous Mycobacteria (NTM) and Tuberculous Mycobacteria (TM) infection or related bronchiectasis in the past 12 months;
- Patient with a positive test for active Allergic Bronchopulmonary Aspergillosis (ABPA) infection confirmed at screening or patient with ABPA related bronchiectasis;
- Patient with Connective Tissue Disease (CTD) related bronchiectasis;
- Diagnosis of common variable immunodeficiency (CVID);
- Patient on any antibiotics (except for stable macrolides treatment),oral, inhaled and IV, within 4 weeks prior to screening or prior to randomisation;
- Patient on oral corticosteroids within 4 weeks prior to screening visit or prior to randomization.
- Patient on non-steroidal anti-inflammatory drugs (NSAIDs) within 4 weeks prior to screening or randomization visit.
- Patient on Carbocysteine and Mannitol treatment within 4 weeks before the screening or randomization visit.
- Patient with traction bronchiectasis;
- Patient with any condition that prevent them to use inhaledantibiotics (including patients who previously experienced adverse reaction to inhaled antibiotics;
- Patient treated with monoclonal antibodies (mAb);
- Pregnant or lactating women.
- Positive HIV1 or HIV2 serology at screening; Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening (i.e. positive HB surface antigen (HBsAg), HBcore antibody (anti-HBc), HC antibody).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CHF6333
CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level). CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days. |
CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
|
PLACEBO_COMPARATOR: CHF6333 Placebo
Part I (SAD): Single dose of placebo matching CHF6333 at each period Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days |
Placebo - Part I - SAD Placebo Part II - MAD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse event
Time Frame: Part I: Baseline through end of treatment (up to a maximum of 30 days after last study drug intake) ; Part II Baseline through end of treatment (up to a maximum of 30 days after last study drug intake)
|
Occurrence and severity of adverse events
|
Part I: Baseline through end of treatment (up to a maximum of 30 days after last study drug intake) ; Part II Baseline through end of treatment (up to a maximum of 30 days after last study drug intake)
|
Change in Vital signs
Time Frame: Part I: Day 1 pre-dose up to 6 hours post dose. Part II: Day 1 and Day 7 pre dose up to 6 hours post dose
|
Change in Systolic and Diastolic blood pressure
|
Part I: Day 1 pre-dose up to 6 hours post dose. Part II: Day 1 and Day 7 pre dose up to 6 hours post dose
|
Heart Rate
Time Frame: Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose
|
Change in Heart Rate
|
Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose
|
PR interval
Time Frame: Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose
|
Change in PR interval
|
Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose
|
QRS interval
Time Frame: Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose
|
Change in QRS interval
|
Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose
|
QTCf interval
Time Frame: Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose
|
Change in QTCf interval
|
Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose
|
FEV1
Time Frame: Part I: Day 1 pre dose up to 6 hours post dose. Part II: Day 1 and Day 7 pre dose up to 6 hours post dose. Day 2 -6: pre dose up to 2 hours post dose
|
Change in FEV1
|
Part I: Day 1 pre dose up to 6 hours post dose. Part II: Day 1 and Day 7 pre dose up to 6 hours post dose. Day 2 -6: pre dose up to 2 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC
Time Frame: Part I: Day 1. Part II Day 1-7
|
Area under the plasma concentration curve
|
Part I: Day 1. Part II Day 1-7
|
Cmax
Time Frame: Part I: Day 1. Part II Day 1-7
|
Peak plasma concentration
|
Part I: Day 1. Part II Day 1-7
|
T max
Time Frame: Part I: Day 1. Part II Day 1-7
|
Time to reach the maximum plasma concentration
|
Part I: Day 1. Part II Day 1-7
|
C24h
Time Frame: Part II: Day 5 Day 6
|
Trough drug concentration 24 h post dose
|
Part II: Day 5 Day 6
|
Rac
Time Frame: Part II: Day 7
|
Accumulation ratio
|
Part II: Day 7
|
NE activity
Time Frame: Part I: Day -1 Day 1. Part II: Day -1 - 7
|
Change in neutrophil elastase activity in sputum
|
Part I: Day -1 Day 1. Part II: Day -1 - 7
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLI-06333AA1-16
- 2018-002508-15 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on CHF 6333
-
Chiesi Farmaceutici S.p.A.SGS S.A.Completed
-
CERESPIRCompletedAlzheimer's DiseaseUnited States
-
Samsung ElectronicsNexus DXTerminatedCongestive Heart FailureUnited States
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD)United Kingdom
-
Yaounde Central HospitalEnrolling by invitationChronic Heart Failure (CHF)Cameroon
-
Chiesi Farmaceutici S.p.A.Completed
-
University of Alabama at BirminghamNational Palliative Care Research Center (NPCRC)CompletedHeart Failure, CongestiveUnited States
-
LivaNovaCompletedHeart Failure | CardiomyopathyNetherlands, France, Spain, Italy, Germany, United Kingdom
-
Chiesi Farmaceutici S.p.A.Completed
-
Chiesi Farmaceutici S.p.A.Completed